Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1878 3
1905 1
1906 1
1908 1
1911 1
1915 1
1916 3
1918 2
1921 1
1922 1
1924 1
1929 1
1931 2
1935 2
1936 5
1937 4
1938 1
1939 3
1940 1
1941 1
1945 3
1946 16
1947 12
1948 12
1949 16
1950 12
1951 19
1952 14
1953 23
1954 16
1955 22
1956 14
1957 19
1958 25
1959 24
1960 22
1961 24
1962 25
1963 38
1964 44
1965 41
1966 48
1967 52
1968 61
1969 62
1970 63
1971 76
1972 72
1973 85
1974 70
1975 74
1976 107
1977 73
1978 83
1979 81
1980 91
1981 101
1982 92
1983 97
1984 114
1985 134
1986 140
1987 147
1988 128
1989 134
1990 126
1991 117
1992 126
1993 132
1994 142
1995 141
1996 121
1997 138
1998 126
1999 142
2000 142
2001 170
2002 169
2003 186
2004 209
2005 254
2006 226
2007 262
2008 254
2009 232
2010 210
2011 272
2012 306
2013 297
2014 307
2015 311
2016 325
2017 310
2018 384
2019 292
2020 385
2021 382
2022 380
2023 340
2024 372
2025 244

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,523 results

Results by year

Filters applied: . Clear all
Page 1
The somatic genomic landscape of glioblastoma.
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. Brennan CW, et al. Among authors: wilson r. Cell. 2013 Oct 10;155(2):462-77. doi: 10.1016/j.cell.2013.09.034. Cell. 2013. PMID: 24120142 Free PMC article.
Patterns and functional implications of rare germline variants across 12 cancer types.
Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, Huang KL, Wyczalkowski MA, Jayasinghe R, Banerjee T, Ning J, Tripathi P, Zhang Q, Niu B, Ye K, Schmidt HK, Fulton RS, McMichael JF, Batra P, Kandoth C, Bharadwaj M, Koboldt DC, Miller CA, Kanchi KL, Eldred JM, Larson DE, Welch JS, You M, Ozenberger BA, Govindan R, Walter MJ, Ellis MJ, Mardis ER, Graubert TA, Dipersio JF, Ley TJ, Wilson RK, Goodfellow PJ, Raphael BJ, Chen F, Johnson KJ, Parvin JD, Ding L. Lu C, et al. Among authors: wilson rk. Nat Commun. 2015 Dec 22;6:10086. doi: 10.1038/ncomms10086. Nat Commun. 2015. PMID: 26689913 Free PMC article.
Targeting STING oligomerization with small-molecule inhibitors.
Humphries F, Shmuel-Galia L, Jiang Z, Zhou JY, Barasa L, Mondal S, Wilson R, Sultana N, Shaffer SA, Ng SL, Pesiridis GS, Thompson PR, Fitzgerald KA. Humphries F, et al. Among authors: wilson r. Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2305420120. doi: 10.1073/pnas.2305420120. Epub 2023 Aug 7. Proc Natl Acad Sci U S A. 2023. PMID: 37549268 Free PMC article.
A roadmap for affordable genetic medicines.
Kliegman M, Zaghlula M, Abrahamson S, Esensten JH, Wilson RC, Urnov FD, Doudna JA. Kliegman M, et al. Among authors: wilson rc. Nature. 2024 Oct;634(8033):307-314. doi: 10.1038/s41586-024-07800-7. Epub 2024 Jul 17. Nature. 2024. PMID: 39019069 Free article. Review.
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, Langhough RE, Cody K, Wilson R, Carlsson CM, Vanmechelen E, Montoliu-Gaya L, Lantero-Rodriguez J, Rahmouni N, Tissot C, Stevenson J, Servaes S, Therriault J, Pascoal T, Lleó A, Alcolea D, Fortea J, Rosa-Neto P, Johnson S, Jeromin A, Blennow K, Zetterberg H. Ashton NJ, et al. Among authors: wilson r. JAMA Neurol. 2024 Mar 1;81(3):255-263. doi: 10.1001/jamaneurol.2023.5319. JAMA Neurol. 2024. PMID: 38252443 Free PMC article.
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.
Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazancıoğlu R, Lamb E, Lin P, Madero M, McIntyre N, Morrow K, Roberts G, Sabanayagam D, Schaeffner E, Shlipak M, Shroff R, Tangri N, Thanachayanont T, Ulasi I, Wong G, Yang CW, Zhang L, Robinson KA, Wilson L, Wilson RF, Kasiske BL, Cheung M, Earley A, Stevens PE. Levin A, et al. Among authors: wilson rf. Kidney Int. 2024 Apr;105(4):684-701. doi: 10.1016/j.kint.2023.10.016. Kidney Int. 2024. PMID: 38519239 Free article.
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.
Mannion J, Gifford V, Bellenie B, Fernando W, Ramos Garcia L, Wilson R, John SW, Udainiya S, Patin EC, Tiu C, Smith A, Goicoechea M, Craxton A, Moraes de Vasconcelos N, Guppy N, Cheung KJ, Cundy NJ, Pierrat O, Brennan A, Roumeliotis TI, Benstead-Hume G, Alexander J, Muirhead G, Layzell S, Lyu W, Roulstone V, Allen M, Baldock H, Legrand A, Gabel F, Serrano-Aparicio N, Starling C, Guo H, Upton J, Gyrd-Hansen M, MacFarlane M, Seddon B, Raynaud F, Roxanis I, Harrington K, Haider S, Choudhary JS, Hoelder S, Tenev T, Meier P. Mannion J, et al. Among authors: wilson r. Immunity. 2024 Jul 9;57(7):1514-1532.e15. doi: 10.1016/j.immuni.2024.04.025. Epub 2024 May 23. Immunity. 2024. PMID: 38788712 Free PMC article.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Among authors: wilson r. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Among authors: wilson r. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
10,523 results
You have reached the last available page of results. Please see the User Guide for more information.